The Global Gastrointestinal Drugs Market Research Report provides detailed analysis of the key regional market status of the Healthcare Industry.
The global Gastrointestinal Drug Market is expected to grow at CAGR of 4.8% during forecasted period 2017- 2023. It is estimated to reach till USD $ 59.3 billion by end of 2024.
Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation and many more. According to a report by the World Gastroenterology Organization, 35-40 % of world’s total population is suffering from acute or chronic GI complication. Increasing patient having GI diseases and disorders, due to change in dietary pattern are the major factor for increasing the global GI drug market. The exact cause for inflammatory bowel disease and Irritable bowel syndrome are still unknown due to which permanent cure for this disease is not available which may restrain the growth of the market.
Top Key Players for Global Gastrointestinal Drugs market: AbbVie Inc. (US), AstraZeneca (UK), Johnson & Johnson (US), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).
Get Sample Reports @ https://www.marketresearchfuture.com/sample_request/558 .
Global Gastrointestinal Drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease Type they are Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. And by End User Hospital Pharmacies, Retail Pharmacies and Other.
Acid Neutralizers which are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and Others,
North America, Europe, Asia Pacific and Middle East and Africa are the four major regional segment of global GI drugs market.. North America account for the largest market share for the global gastrointestinal drug market. Increasing geriatric population is the major driving factor for the market of GI drugs in North America. Europe and Asia Pacific share nearly similar amount of market. Introduction of new drugs and different technology has increased the market in Asia Pacific and Europe. Asia Pacific is the most favourable region for the development of GI drug market. Huge population and infrastructural improvement has increases the scope for the development of this market in coming future.
TABLE OF CONTENTS
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
Get Discount @ https://www.marketresearchfuture.com/check-discount/558 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312